Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution

E-cigarettes may bring about cardiac risk according to a new literature review soon to be published in J Am Coll Cardiol. The evidence on potential harm is not definitive, but some experts suggest caution in their use until there is more solid evidence.

E-cigarettes have been advertised as a healthy alternative to traditional cigarettes and an aid for tobacco cessation, but recent evidence suggests that they might cause adverse cardiovascular events.

 

Such events involve endothelial function, vascular stiffness, vasoconstriction, heart rate, blood pressure, inflammation, oxidative stress, and platelet function (all of which have already been observed with e-cigarettes). While e-cigarettes are widely believed to be safe (in terms of both cardiovascular risk and cancer), the truth is that they have not been studied enough. In fact, we could say that there is not enough solid evidence confirming that e-cigarettes even help people to quit smoking conventional cigarettes.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


These devices can only be considered another tool to help people quit smoking.

 

If they do help smokers to quit conventional cigarettes, their potential for public health benefit is huge. However, this potential benefit must be balanced against their long-term health risks, which are still unknown.

 

Researchers reviewed 14 studies (all of them carried out in developed countries) that suggest possible cardiovascular harm and note that e-cigarettes are available in most countries around the world without any regulation.


Read also: Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy.


We have a responsibility to inform our patients that e-cigarettes contain chemicals whose long-term effects are currently unknown. For smokers, this may be the lesser evil, but we should emphasize the fact that we still lack enough evidence.

 

Original title: 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment.

Reference: Barua RS et al. J Am Coll Cardiol. 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

KISS Trial: provisional stenting in non-left main coronary bifurcations — is less more?

Coronary bifurcation angioplasty remains one of the most frequent and technically challenging scenarios in interventional cardiology. Between 15% and 20% of coronary procedures involve...

Complex radial access: a four-step protocol to overcome loops and tortuosity

Radial access is currently the preferred strategy for coronary angiography and percutaneous coronary interventions due to its lower rates of bleeding and vascular complications...

Percutaneous closure of paravalvular leaks in high-risk patients: clinical outcomes and the impact of residual leak

Paravalvular leak (PVL) is a relatively frequent complication following valve replacement (overall incidence 5–18%; 2–10% in the aortic position and 7–17% in the mitral...